NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

泌尿上皮癌 - 流行病學預測 2028年

Urothelial Carcinoma - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 911523
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
泌尿上皮癌 - 流行病學預測 2028年 Urothelial Carcinoma - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的泌尿上皮癌的2017年的罹患數估算為24萬3,151人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的泌尿上皮癌市場調查,疾病概要,各重病度、年齡、性別、腫瘤階段、轉移階段、各國罹患數的變化與預測,未滿足需求,市場成長要素及障礙等總括性彙整。

目錄

第1章 重要洞察

第2章 疾病背景和概要

  • 簡介
  • 泌尿上皮癌的惡性度
    • G1
    • G3
    • G2
  • 泌尿上皮癌的組織學特徵
  • TNM病期分類系統
  • 泌尿上皮癌的分類
  • 泌尿上皮癌的危險因素
  • 泌尿上皮癌的病因
  • 泌尿上皮癌的分子病因和預後
  • 泌尿上皮癌的生物標記
  • 泌尿上皮癌的診斷

第4章 診斷指南:美國泌尿科學會(AUA)

  • 風險分等級

第5章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的泌尿上皮癌的總罹患數

第6章 泌尿上皮癌的流行病學:各國

  • 美國
    • 假設和根據
    • 泌尿上皮癌的總罹患數
    • 局部進行性/轉移性泌尿上皮癌的罹患數
    • 泌尿上皮癌的罹患數:各重症度
    • 泌尿上皮癌的罹患數:各年齡
    • 泌尿上皮癌的罹患數:性別
    • 泌尿上皮癌的罹患數:腫瘤各階段
    • 泌尿上皮癌的罹患數:各轉移階段
  • 歐洲5個國家
    • 德國
      • 泌尿上皮癌的總罹患數
      • 局部進行性/轉移性泌尿上皮癌的罹患數
      • 泌尿上皮癌的罹患數:各重症度
      • 泌尿上皮癌的罹患數:各年齡
      • 泌尿上皮癌的罹患數:性別
      • 泌尿上皮癌的罹患數:各腫瘤階段
      • 泌尿上皮癌的罹患數:各轉移階段
    • 法國
      • 泌尿上皮癌的總罹患數
      • 局部進行性/轉移性泌尿上皮癌的罹患數
      • 泌尿上皮癌的罹患數:各重症度
      • 泌尿上皮癌的罹患數:各年齡
      • 泌尿上皮癌的罹患數:性別
      • 泌尿上皮癌的罹患數:各腫瘤階段
      • 泌尿上皮癌的罹患數:各轉移階段
    • 義大利
      • 泌尿上皮癌的總罹患數
      • 局部進行性/轉移性泌尿上皮癌的罹患數
      • 泌尿上皮癌的罹患數:各重症度
      • 泌尿上皮癌的罹患數:各年齡
      • 泌尿上皮癌的罹患數:性別
      • 泌尿上皮癌的罹患數:各腫瘤階段
      • 泌尿上皮癌的罹患數:各轉移階段
    • 西班牙
      • 泌尿上皮癌的總罹患數
      • 局部進行性/轉移性泌尿上皮癌的罹患數
      • 泌尿上皮癌的罹患數:各重症度
      • 泌尿上皮癌的罹患數:各年齡
      • 泌尿上皮癌的罹患數:性別
      • 泌尿上皮癌的罹患數:各腫瘤階段
      • 泌尿上皮癌的罹患數:各轉移階段
    • 英國
      • 泌尿上皮癌的總罹患數
      • 局部進行性/轉移性泌尿上皮癌的罹患數
      • 泌尿上皮癌的罹患數:各重症度
      • 泌尿上皮癌的罹患數:各年齡
      • 泌尿上皮癌的罹患數:性別
      • 泌尿上皮癌的罹患數:各腫瘤階段
      • 泌尿上皮癌的罹患數:各轉移階段
  • 日本
    • 泌尿上皮癌的總罹患數
    • 局部進行性/轉移性泌尿上皮癌的罹患數
    • 泌尿上皮癌的罹患數:各重症度
    • 泌尿上皮癌的罹患數:各年齡
    • 泌尿上皮癌的罹患數:性別
    • 泌尿上皮癌的罹患數:各腫瘤階段
    • 泌尿上皮癌的罹患數:各轉移階段

第16章 附錄

第17章 調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIEI0387

DelveInsight's 'Urothelial Carcinoma- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of urothelial carcinoma in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Urothelial Carcinoma Epidemiology

The Urothelial Carcinoma epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for urothelial carcinoma are studied through all possible division to give a better understanding of the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Urothelial Carcinoma Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by:

  • Diagnosed Incident Population of Urothelial Carcinoma
  • Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma
  • Severity-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Age-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Gender-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Tumor (T) stage-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Metastatic stage-specific Diagnosed Incident Population of Urothelial Carcinoma

According to DelveInsight, the total diagnosed incident cases of Urothelial Carcinoma in the seven major markets were 243,151, out of which the total cases of locally advanced/metastatic Urothelial Carcinoma were 96,711 cases in 2017.

Report Scope

  • The report covers the detailed overview of urothelial carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of urothelial carcinoma.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type-specific cases and severity specific cases of urothelial carcinoma in the 7MM.

Key strengths

  • 10-Year Forecast of urothelial carcinoma epidemiology
  • 7MM Coverage
  • Total Incident Cases of urothelial carcinoma
  • Incident Cases according to segmentation

Key assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview: Urothelial Carcinoma (UC)

  • 2.1. Introduction
  • 2.2. Grading of Urothelial carcinoma
    • 2.2.1. G1 tumors
    • 2.2.2. G3 tumors
    • 2.2.3. G2 tumors
  • 3.3 Histological Features of Urothelial Neoplasm
    • 3.3.1 Papillary urothelial neoplasm of low malignant potential (PUNLMP)
    • 3.3.2 Low-grade papillary urothelial carcinoma
    • 3.3.3 High-grade papillary urothelial carcinoma
  • 3.4 TNM Staging System
    • 3.4.1 Stages of urothelial carcinoma
  • 3.5 Classification for Urothelial Carcinoma
    • 3.5.1. Non-invasive inverted urothelial neoplasms
    • 3.5.2. Urothelial dysplasia and carcinoma in situ with "early papillary formation"
    • 3.5.3. Morphologic spectrum of inverted urothelial neoplasms
    • 3.5.4. Invasive urothelial carcinoma
  • 3.6 Risk factors for Urothelial Neoplasm
    • 3.6.1 Cigarette smoke
    • 3.6.2 Analgesics
    • 3.6.3 Genetic effects
    • 3.6.4 Occupational carcinogen exposure
  • 3.7 Pathogenesis for Urothelial Neoplasm
  • 3.8 Molecular pathogenesis and prognostics of bladder cancer for Urothelial carcinoma
    • 3.8.1 The molecular basis of multifocality of urothelial tumors
    • 3.8.2 Urothelial carcinoma phenotypes and their behavior
    • 3.8.3 Molecular classification of urothelial carcinoma
    • 3.8.4 Molecular classification of urothelial carcinoma
  • 3.9 Biomarkers for Urothelial carcinoma
    • 3.9.1 Proteomic and peptidomic analysis
    • 3.9.2 Protein Biomarkers
    • 3.9.3 Transcriptomic Biomarkers
    • 3.9.4 Epigenetic DNA Methylation Markers
    • 3.9.5 cfDNA, mutation, and microsatellite alterations
    • 3.9.6 Urinary tumor RNA
    • 3.9.7 Messenger RNAs (mRNAs) and Transfer RNA fragments (tRFs)
    • 3.9.8 Extracellular vesicles (EVs) and exosomes
  • 3.10 Diagnosis for Urothelial carcinoma
    • 3.10.1 Aura Tek FDP Test
    • 3.10.2 Cystoscopy and Cytology
    • 3.10.3 BTA stat and BTA TRAK
    • 3.10.4 NMP22 BC Test and NMP22 BladderChek Test
    • 3.10.5 ImmunoCyt/uCyt
    • 3.10.6 UroVysion
    • 3.10.7 CertNDx
    • 3.10.8 Cxbladder test
    • 3.10.9 Cytologic-based tests
    • 3.10.10 Urine cytology and FISH
    • 3.10.11 Imaging
    • 3.10.12 Photodynamic diagnosis (PDD)
    • 3.10.13 Endoscopy
    • 3.10.14 New upcoming technologies for diagnosis
    • 3.10.15 Urothelial Carcinoma in Nutshell

4 Diagnostic Guidelines: American Urology Association (AUA)

  • 4.1 Risk Stratification
    • 4.1.1 Variant Histology
    • 4.1.2 Urine marker after diagnosis of bladder Cancer
    • 4.1.3 TURBT/Repeat Resection: Timing, Technique, Goal, Indication
    • 4.1.4 Intravesical Therapy; BCG/Maintenance; Chemotherapy/BCG Combinations
    • 4.1.5 BCG Relapse and Salvage Regimen

5 Epidemiology and Patient Population

  • 5.1 Key Findings
  • 5.2 7MM Total Diagnosed Incident Patient Population of Urothelial Carcinoma

6 Country Wise-Epidemiology of Urothelial Carcinoma

  • 6.1 United States
    • 6.1.1 Assumptions and Rationale
    • 6.1.2 Urothelial Carcinoma Diagnosed Incident Population in the United States
    • 6.1.3 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States
    • 6.1.4 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States
    • 6.1.5 Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States
    • 6.1.6 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States
    • 6.1.7 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States
    • 6.1.8 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States
  • 6.2 EU5 Countries
    • 6.2.1 Assumptions and Rationale
  • 6.3 Germany
    • 6.3.1 Diagnosed Incident Population in Germany
    • 6.3.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany
    • 6.3.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany
    • 6.3.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany
    • 6.3.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany
    • 6.3.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany
    • 6.3.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany
  • 6.4 France
    • 6.4.1 Urothelial Carcinoma Diagnosed Incident Population in France
    • 6.4.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France
    • 6.4.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France
    • 6.4.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in France
    • 6.4.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France
    • 6.4.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France
    • 6.4.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France
  • 6.5 Italy
    • 6.5.1 Urothelial Carcinoma Diagnosed Incident Population in Italy
    • 6.5.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy
    • 6.5.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy
    • 6.5.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy
    • 6.5.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy
    • 6.5.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy
    • 6.5.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy
  • 6.6 Spain
    • 6.6.1 Urothelial Carcinoma Diagnosed Incident Population in Spain
    • 6.6.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain
    • 6.6.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Spain
    • 6.6.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain
    • 6.6.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain
    • 6.6.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain
    • 6.6.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain
  • 6.7 United Kingdom
    • 6.7.1 Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom
    • 6.7.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom
    • 6.7.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom
    • 6.7.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom
    • 6.7.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom
    • 6.7.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom
    • 6.7.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom
  • 6.8 Japan
    • 6.8.1 Assumptions and Rationale
    • 6.8.2 Urothelial Carcinoma Diagnosed Incident Population in Japan
    • 6.8.3 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan
    • 6.8.4 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan
    • 6.8.5 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan
    • 6.8.6 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan
    • 6.8.7 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan
    • 6.8.8 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan

16 Appendix

17 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

  • Table 1: Histological features of papillary urothelial lesions
  • Table 2: TNM staging system
  • Table 3: Sub-grouping of the non-invasive urothelial neoplasms with an inverted growth pattern
  • Table 4: FDA-approved urinary biomarkers for the detection of bladder cancer
  • Table 5: Performance of Markers in Surveillance Setting from Pooled Analyses
  • Table 6: AUA Nomenclature Linking Statement Type to Level of Certainty, Magnitude of Benefit or Risk/Burden, and Body of Evidence Strength
  • Table 7: Staging of primary tumors (T) in bladder cancer
  • Table 8: 2004 World Health Organization/International Society of Urologic Pathologists: Classification of Non-muscle Invasive Urothelial Neoplasia
  • Table 9: AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer
  • Table 10: Urothelial Carcinoma Total Diagnosed Incident Population in the 7MM (2017-2028)
  • Table 11: Urothelial Carcinoma Diagnosed Incident Population in the United States (2017-2028)
  • Table 12: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States (2017-2028)
  • Table 13: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States (2017-2028)
  • Table 14: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States (2017-2028)
  • Table 15: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States (2017-2028)
  • Table 16: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States (2017-2028)
  • Table 17: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States (2017-2028)
  • Table 18: Urothelial Carcinoma Diagnosed Incident Population in Germany (2017-2028)
  • Table 19: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany (2017-2028)
  • Table 20: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany (2017-2028)
  • Table 21: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany (2017-2028)
  • Table 22: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany (2017-2028)
  • Table 23: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany (2017-2028)
  • Table 24: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany (2017-2028)
  • Table 25: Urothelial Carcinoma Diagnosed Incident Population in France (2017-2028)
  • Table 26: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France (2017-2028)
  • Table 27: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France(2017-2028)
  • Table 28: Urothelial Carcinoma Age-specific Diagnosed Incident Population in France (2017-2028)
  • Table 29: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France (2017-2028)
  • Table 30: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France (2017-2028)
  • Table 31: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France (2017-2028)
  • Table 32: Urothelial Carcinoma Diagnosed Incident Population in Italy(2017-2028)
  • Table 33: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy (2017-2028)
  • Table 34: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy (2017-2028)
  • Table 35: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy (2017-2028)
  • Table 36: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy (2017-2028)
  • Table 37: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy (2017-2028)
  • Table 38: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy (2017-2028)
  • Table 39: Urothelial Carcinoma Diagnosed Incident Population in Spain (2017-2028)
  • Table 40: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain (2017-2028)
  • Table 41: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Spain (2017-2028)
  • Table 42: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain (2017-2028)
  • Table 43: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain (2017-2028)
  • Table 44: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain (2017-2028)
  • Table 45: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain (2017-2028)
  • Table 46: Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Table 47: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom (2017-2028)
  • Table 48: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Table 49: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Table 50: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Table 51: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Table 52: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Table 53: Urothelial Carcinoma Diagnosed Incident Population in Japan (2017-2028)
  • Table 54: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan (2017-2028)
  • Table 55: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan (2017-2028)
  • Table 56: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan (2017-2028)
  • Table 57: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan (2017-2028)
  • Table 58: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan (2017-2028)
  • Table 59: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan (2017-2028)

List of Figures

  • Figure 1: Histological grading of papillary urothelial neoplasms. (a) Benign urothelial papilloma; (b) papillary urothelial neoplasm of low malignant potential; (c) low-grade papillary urothelial carcinoma; and (d) high-grade papillary urothelial carcinoma.
  • Figure 2: Schematic representation of the two major pathways of urothelial carcinogenesis: Note that
  • Figure 3: Molecular Biology of bladder cancer
  • Figure 4: Monitoring of Biomarkers
  • Figure 5: Urothelial Carcinoma Total Diagnosed Incident Patient Population in the 7MM (2017-2028)
  • Figure 6: Urothelial Carcinoma Diagnosed Incident Population in the United States (2017-2028)
  • Figure 7: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States (2017-2028)
  • Figure 8: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States (2017-2028)
  • Figure 9: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States (2017-2028)
  • Figure 10: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States (2017-2028)
  • Figure 11: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States (2017-2028)
  • Figure 12: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States (2017-2028)
  • Figure 13: Urothelial Carcinoma Diagnosed Incident Population in Germany (2017-2028)
  • Figure 14: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany (2017-2028)
  • Figure 15: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany (2017-2028)
  • Figure 16: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany (2017-2028)
  • Figure 17: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany (2017-2028)
  • Figure 18: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany (2017-2028)
  • Figure 19: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany (2017-2028)
  • Figure 20: Urothelial Carcinoma Diagnosed Incident Population in France (2017-2028)
  • Figure 21: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France (2017-2028)
  • Figure 22: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France (2017-2028)
  • Figure 23: Urothelial Carcinoma Age-specific Diagnosed Incident Population in France (2017-2028)
  • Figure 24: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France (2017-2028)
  • Figure 25: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France (2017-2028)
  • Figure 26: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France (2017-2028)
  • Figure 27: Urothelial Carcinoma Diagnosed Incident Population in Italy (2017-2028)
  • Figure 28: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy (2017-2028)
  • Figure 29: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy (2017-2028)
  • Figure 30: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy (2017-2028)
  • Figure 31: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy (2017-2028)
  • Figure 32: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy (2017-2028)
  • Figure 33: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy (2017-2028)
  • Figure 34: Urothelial Carcinoma Diagnosed Incident Population in Spain (2017-2028)
  • Figure 35: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain (2017-2028)
  • Figure 36: Urothelial Carcinoma Severity-specific Diagnosed Incident Population of in Spain (2017-2028)
  • Figure 37: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain (2017-2028)
  • Figure 38: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain (2017-2028)
  • Figure 39: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain (2017-2028)
  • Figure 40: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain (2017-2028)
  • Figure 41: Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Figure 42: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom (2017-2028)
  • Figure 43: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Figure 44: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Figure 45: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Figure 46: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Figure 47: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)
  • Figure 48: Urothelial Carcinoma Diagnosed Incident Population in Japan (2017-2028)
  • Figure 49: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan (2017-2028)
  • Figure 50: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan (2017-2028)
  • Figure 51: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan (2017-2028)
  • Figure 52: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan (2017-2028)
  • Figure 53: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan (2017-2028)
  • Figure 54: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan (2017-2028)
  • Figure 55: Unmet Needs of Urothelial Carcinoma